- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00016861
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
Pediatric Phase I and Pharmacokinetic Study of Irinotecan
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan in children with refractory or progressive solid tumors.
- Determine the pharmacokinetics of this drug and its metabolites (SN-38, SN-38G, and APC) administered with and without concurrent anticonvulsants in this patient population.
- Determine the benefit this drug offers this patient population.
OUTLINE: This is a dose-escalation, multicenter study. Patients are accrued into stratum 1 initially and into stratum 2 if stratum 1 closes due to dose-limiting toxicity of myelosuppression or diarrhea. Patients on anticonvulsants will be accrued into stratum 3 and must meet the eligibility criteria for the stratum that is open (stratum 1 or stratum 2). (Stratum 1 closed as of 2002-09-15).
Patients receive irinotecan IV over 90 minutes weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) with and without anticonvulsants is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.
Tipo de estudo
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-2399
- Texas Children's Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed solid tumor refractory to standard therapy or for which no known effective therapy exists
Brain tumors eligible
- Histologic verification waived for brain stem gliomas
- Evaluable disease
- No bone marrow involvement
PATIENT CHARACTERISTICS:
Age:
- 1 to 21
Performance status:
- Karnofsky 50-100% (over age 10)
- Lansky 50-100% (age 10 and under)
Life expectancy:
- At least 8 weeks
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin less than 1.5 mg/dL
- SGPT less than 5 times normal
Renal:
- Creatinine normal OR
- Glomerular filtration rate at least 70 mL/min
Other:
- No uncontrolled infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 6 months since prior autologous bone marrow transplantation (BMT) (not including stem cell rescue after high-dose chemotherapy)
- At least 1 week since prior growth factors
- No prior BMT with total body irradiation (stratum I)
- No prior BMT with or without total body irradiation (stratum 2)
- No prior allogeneic BMT (all strata)
- No concurrent sargramostim (GM-CSF)
- No other concurrent prophylactic growth factor support during the first course of therapy
Chemotherapy:
- At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
- No prior irinotecan
- No more than 2 prior multi-agent chemotherapy regimens (stratum 2)
- No other concurrent chemotherapy
Endocrine therapy:
- Concurrent dexamethasone allowed if on stable or decreasing dose for at least 2 weeks prior to study
Radiotherapy:
- At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of the pelvis
- At least 6 weeks since other prior substantial bone marrow radiotherapy
- No prior central axis radiotherapy, pelvic radiotherapy, and/or total abdominal radiotherapy (stratum 2)
Surgery:
- Not specified
Other:
- Recovered from all prior therapy
- No other concurrent investigational agents
- Concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine) allowed if on stable dose for at least 2 weeks prior to study (stratum 3)
- Concurrent valproic acid allowed if combined with another enzyme inducing anticonvulsant drug (stratum 3)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Susan M. Blaney, MD, Texas Children's Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TCCC-H-6957
- CDR0000068568 (Identificador de registro: PDQ (Physician Data Query))
- TCCC-GCRC-0654
- NCI-V01-1654
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em cloridrato de irinotecano
-
Boston Scientific CorporationBiocompatibles UK LtdConcluídoCâncer Colorretal MetastáticoReino Unido, Áustria, França
-
Generic Devices Consulting, Inc.Biocompatibles UK LtdRescindidoCâncer Colorretal Metastático IrressecávelEstados Unidos
-
Dutch Colorectal Cancer GroupSanofi; Hoffmann-La Roche; Koningin Wilhelmina FondsConcluídoCâncer Colorretal Avançado
-
Centro Ricerche Cliniche di VeronaRecrutamentoAdenocarcinoma pancreáticoItália
-
Jiangsu HengRui Medicine Co., Ltd.ConcluídoTumores Sólidos AvançadosChina
-
Beijing Sanbo Brain HospitalRecrutamentoGlioblastoma Recorrente | Glioma de Grau Inferior, RecorrenteChina
-
GERCOR - Multidisciplinary Oncology Cooperative...OSE ImmunotherapeuticsRecrutamentoCâncer metastático | Adenocarcinoma Ductal Pancreático | Câncer Localmente AvançadoFrança
-
Peking Union Medical College HospitalRecrutamentoCâncer retal | Cancer de colo | Efeito da Quimioterapia | PTC | Mutação ExonChina
-
Cornerstone PharmaceuticalsConcluídoCâncer de Pâncreas MetastáticoEstados Unidos, Republica da Coréia, França, Israel, Alemanha, Bélgica
-
Massachusetts General HospitalStand Up To CancerRecrutamentoCâncer de cólon metastático | Câncer de cólon estágio IIIEstados Unidos